ha-loe-PER-i-dole 
Unlabeled Use:
Absorption: Well absorbed following PO/IM administration. Decanoate salt is slowly absorbed and has a long duration of action.
Distribution: Concentrates in liver. Crosses placenta; enters breast milk.
Protein Binding: 92%.
Metabolism/Excretion: Mostly metabolized by the liver.
Half-life: 21–24 hr.
Contraindicated in:
Use Cautiously in:
CV: TORSADES DE POINTES, hypotension, QT interval prolongation, tachycardia, ventricular arrhythmias.
Derm: diaphoresis, photosensitivity, rash.
EENT: blurred vision, dry eyes.
Endo: amenorrhea, galactorrhea, gynecomastia.
GI: constipation, dry mouth, anorexia, drug-induced hepatitis, ileus, weight gain.
GU: impotence, urinary retention.
Hemat: AGRANULOCYTOSIS, anemia, leukopenia, neutropenia.
Metab: hyperpyrexia.
Neuro: SEIZURES, extrapyramidal reactions, confusion, drowsiness, restlessness, tardive dyskinesia.
Resp: respiratory depression.
Misc: NEUROLEPTIC MALIGNANT SYNDROME, hypersensitivity reactions.
Drug-Drug:
Drug-Natural Products:
Haloperidol
Haloperidol Decanoate
IV Administration:
(Generic available)
(antipsychotic activity)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | 2 hr | 2–6 hr | 8–12 hr |
| IM | 20–30 min | 30–45 min | 4–8 hr† |
| IM (decanoate) | 3–9 days | unknown | 1 mo |
NDC Code*